Invion’s Stock Plunges 11% as Company Launches Troubling Share‑Option Issue
Invion’s stock dives 11% as the biotech faces liquidity woes and a controversial share‑option issuance, signaling deep doubts about its future and investor confidence.
3 minutes to read
